OBJECTIVE： To evaluate the efficacy and safety of Danqipiantan capsule （DPC） for the treatment of stroke. METHODS： PubMed, China Science And Technolo- gy Journal Database, Wanfang Database, Chinese periodicals in ...OBJECTIVE： To evaluate the efficacy and safety of Danqipiantan capsule （DPC） for the treatment of stroke. METHODS： PubMed, China Science And Technolo- gy Journal Database, Wanfang Database, Chinese periodicals in the China National Knowledge Infra- structure, and the General Hospital of Tianjin Medi- cal University＇s Library were searched until July 2012. Randomized controlled trials （RCTs） and ob- servational studies that reported the use of DPC for treatment of stroke were selected. RESULTS： Eleven articles that included 12 RCTs, and 2 articles that included 3 observational studies were identified. A total of 2590 patients participat- ed in the studies. We found that there was a signifi-cant statistical difference between DPC treatment groups and the control groups in terms of the effec- tive rate [risk ratio （RR）, 1.14; 95% confidence inter- vals （CI）, 1.04, 1.25; P=0.01], FugI-Meyer Assessment Scale [weighted mean difference （WMD）, 9.77; 95% CI （4.84, 14.70）; P=0.00], Barthel Index [WMD=6.40; 95% CI （3.15, 9.65）], and mean flow velocity [WMD= 5.79; 95% CI （1.64, 9.94）]. There were no significant differences for The National Institutes of Health Stroke Scale [WMD=0.60; 95% CI （ - 1.09, 2.29）], vi- sual field defects [left visual field： WMD= - 203.10; 95% CI （ - 424.41, 18.21）; right visual field： WMD= - 172.60; 95% CI （ - 409.29, 64.09）] or the functional independence measure [WMD= - 7.90; 95% CI （ - 16.64, 0.84）]. Seven articles that included eight RCTs reported the safety of DPC treatment. Two ar- ticles that included three observational studies also reported beneficial effects for DPC. Because the Chinese studies were of poor methodological quali- ty, and most of the sample sizes were small, our analysis was likely affected by bias. CONCLUSION： DPC has a beneficial effect and is relatively safe when used for the treatment of stroke.展开更多
基金Supported by The National Science and Technology Infrastructure Program of China(2006BAI04A02-2)the National Basic Research Program of China(2012CB518505)the Natural Science Foundation of China(81173416)
文摘OBJECTIVE： To evaluate the efficacy and safety of Danqipiantan capsule （DPC） for the treatment of stroke. METHODS： PubMed, China Science And Technolo- gy Journal Database, Wanfang Database, Chinese periodicals in the China National Knowledge Infra- structure, and the General Hospital of Tianjin Medi- cal University＇s Library were searched until July 2012. Randomized controlled trials （RCTs） and ob- servational studies that reported the use of DPC for treatment of stroke were selected. RESULTS： Eleven articles that included 12 RCTs, and 2 articles that included 3 observational studies were identified. A total of 2590 patients participat- ed in the studies. We found that there was a signifi-cant statistical difference between DPC treatment groups and the control groups in terms of the effec- tive rate [risk ratio （RR）, 1.14; 95% confidence inter- vals （CI）, 1.04, 1.25; P=0.01], FugI-Meyer Assessment Scale [weighted mean difference （WMD）, 9.77; 95% CI （4.84, 14.70）; P=0.00], Barthel Index [WMD=6.40; 95% CI （3.15, 9.65）], and mean flow velocity [WMD= 5.79; 95% CI （1.64, 9.94）]. There were no significant differences for The National Institutes of Health Stroke Scale [WMD=0.60; 95% CI （ - 1.09, 2.29）], vi- sual field defects [left visual field： WMD= - 203.10; 95% CI （ - 424.41, 18.21）; right visual field： WMD= - 172.60; 95% CI （ - 409.29, 64.09）] or the functional independence measure [WMD= - 7.90; 95% CI （ - 16.64, 0.84）]. Seven articles that included eight RCTs reported the safety of DPC treatment. Two ar- ticles that included three observational studies also reported beneficial effects for DPC. Because the Chinese studies were of poor methodological quali- ty, and most of the sample sizes were small, our analysis was likely affected by bias. CONCLUSION： DPC has a beneficial effect and is relatively safe when used for the treatment of stroke.
